✦ LIBER ✦

Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: A two-phase randomized controlled trial

✍ Scribed by Lofwall, Michelle R.; Babalonis, Shanna; Nuzzo, Paul A.; Siegel, Anthony; Campbell, Charles; Walsh, Sharon L.

Book ID: 122586728
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 864 KB
Volume: 133
Category: Article
ISSN: 0376-8716
DOI: 10.1016/j.drugalcdep.2013.05.010

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Extended-release tramadol in the treatme

Extended-release tramadol in the treatment of osteoarthritis:a multicenter, randomized, double-blind, placebo-controlled clinical trial

✍ Gana, Theophilus J.; Pascual, Maria Luz G.; Fleming, Rosa Rosanna B.; Schein, Je 📂 Article 📅 2006 🏛 Informa plc 🌐 English ⚖ 592 KB

Extended-release methylphenidate for tre

Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial

✍ Miles, S. Wayne; Sheridan, Janie; Russell, Bruce; Kydd, Rob; Wheeler, Amanda; Wa 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 282 KB

Efficacy and tolerability of extended re

Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial

✍ Michael Liebowitz; Raymond W. Lam; Ulla Lepola; Catherine Datto; Dennis Sweitzer 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 1 views

Health-related outcomes associated with

✍ Etropolski, M.; Kleinert, R.; Shapiro, D.Y.; Okamoto, A.; Lange, R.; Rauschkolb, 📂 Article 📅 2009 🏛 Canadian Diabetes Association 🌐 English ⚖ 436 KB

A double-blind, randomized, placebo-cont

A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression

✍ Richard L Rudolph; Alan D Feiger 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 225 KB

Sensitivity analyses of the primary effi

Sensitivity analyses of the primary efficacy endpoint in a randomized-withdrawal phase 3 trial of tapentadol extended release (ER) in patients with painful diabetic peripheral neuropathy (DPN)

✍ Etropolski, M.; Steup, A.; Shapiro, D.Y.; Okamoto, A.; Haeussler, J. 📂 Article 📅 2009 🏛 Canadian Diabetes Association 🌐 English ⚖ 448 KB